Literature DB >> 33408736

Identification and Validation of Two Lung Adenocarcinoma-Development Characteristic Gene Sets for Diagnosing Lung Adenocarcinoma and Predicting Prognosis.

Cheng Liu1, Xiang Li2, Hua Shao2, Dan Li2.   

Abstract

Background: Lung adenocarcinoma (LUAD) is one of the main types of lung cancer. Because of its low early diagnosis rate, poor late prognosis, and high mortality, it is of great significance to find biomarkers for diagnosis and prognosis.
Methods: Five hundred and twelve LUADs from The Cancer Genome Atlas were used for differential expression analysis and short time-series expression miner (STEM) analysis to identify the LUAD-development characteristic genes. Survival analysis was used to identify the LUAD-unfavorable genes and LUAD-favorable genes. Gene set variation analysis (GSVA) was used to score individual samples against the two gene sets. Receiver operating characteristic (ROC) curve analysis and univariate and multivariate Cox regression analysis were used to explore the diagnostic and prognostic ability of the two GSVA score systems. Two independent data sets from Gene Expression Omnibus (GEO) were used for verifying the results. Functional enrichment analysis was used to explore the potential biological functions of LUAD-unfavorable genes.
Results: With the development of LUAD, 185 differentially expressed genes (DEGs) were gradually upregulated, of which 84 genes were associated with LUAD survival and named as LUAD-unfavorable gene set. While 237 DEGs were gradually downregulated, of which 39 genes were associated with LUAD survival and named as LUAD-favorable gene set. ROC curve analysis and univariate/multivariate Cox proportional hazards analyses indicated both of LUAD-unfavorable GSVA score and LUAD-favorable GSVA score were a biomarker of LUAD. Moreover, both of these two GSVA score systems were an independent factor for LUAD prognosis. The LUAD-unfavorable genes were significantly involved in p53 signaling pathway, Oocyte meiosis, and Cell cycle.
Conclusion: We identified and validated two LUAD-development characteristic gene sets that not only have diagnostic value but also prognostic value. It may provide new insight for further research on LUAD.
Copyright © 2020 Liu, Li, Shao and Li.

Entities:  

Keywords:  The Cancer Genome Atlas; gene set variation analysis score; lung adenocarcinoma; predicting prognosis; prognostic stratification system

Year:  2020        PMID: 33408736      PMCID: PMC7779611          DOI: 10.3389/fgene.2020.565206

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


  4 in total

1.  Modulation of Tumor Immune Microenvironment and Prognostic Value of Ferroptosis-Related Genes, and Candidate Target Drugs in Glioblastoma Multiforme.

Authors:  Xudong Zhang; Shengnan Jin; Xin Shi; Shengyu Liu; Kunhang Li; Guojun Liu; Shiyu Zhong; Tao Liu; Lishuai Li; Shanwei Tao; Qingqing Zhai; Nan Bao; Lijie Ren; Ying Wu; Yijun Bao
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

2.  Junctional Adhesion Molecule-Like Protein (JAML) Is Correlated with Prognosis and Immune Infiltrates in Lung Adenocarcinoma.

Authors:  Likui Fang; Wenfeng Yu; Guocan Yu; Fangming Zhong; Bo Ye
Journal:  Med Sci Monit       Date:  2022-01-16

3.  The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases.

Authors:  Juan Zhou; Yinfei Wu; Mengqing Xie; Yujia Fang; Jing Zhao; Sung Yong Lee; Yunjoo Im; Lingyun Ye; Chunxia Su
Journal:  Transl Lung Cancer Res       Date:  2022-04

4.  In silico assessment of EpCAM transcriptional expression and determination of the prognostic biomarker for human lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).

Authors:  Abu Tayab Moin; Bishajit Sarkar; Md Asad Ullah; Yusha Araf; Nafisa Ahmed; Bashudev Rudra
Journal:  Biochem Biophys Rep       Date:  2021-07-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.